CAR T-cell therapy ‘sees’ solid tumours thanks to protein, Pg12

Key Highlights:

• Researchers have developed a new CAR T-cell therapy specifically designed to target rare solid tumors.
• The therapy identifies and targets the protein GPNMB, which is consistently expressed on these tumor cells.
• It has shown promise in treating alveolar soft-part sarcoma (ASPS) and certain kidney cancers.
• A patient with advanced ASPS experienced disease stabilization for three months and regression of several smaller tumors.
• The treatment was well-tolerated, and combining it with immune checkpoint blockers may help overcome treatment resistance.

CART.png

Detailed Insights:

• CAR T-cell therapy involves extracting a patient's T-cells, genetically engineering them to recognize cancer cells, and then reinfusing them into the patient.
• Solid tumors are abnormal masses of tissue that form in organs, distinguishing them from liquid cancers like leukemia.
• Alveolar soft-part sarcoma (ASPS) is a rare and aggressive soft tissue cancer that typically affects young adults and is known for its tendency to metastasize early, often to the lungs and brain.
• The protein GPNMB (glycoprotein nonmetastatic melanoma protein B) is a transmembrane glycoprotein involved in various cellular functions, now identified as a crucial target for this therapy.
• This development represents a significant advancement in extending the efficacy of CAR T-cell therapy beyond blood cancers to solid tumors, which have historically been more challenging to treat with this method.
• Immune checkpoint blockers are a class of drugs that prevent cancer cells from deactivating T-cells, thereby enhancing the body's immune response against tumors.

Scientific/Technical Concepts Involved:

• CAR T-cell Therapy: A form of immunotherapy where a patient's T-cells are genetically modified to express Chimeric Antigen Receptors (CARs), enabling them to specifically recognize and destroy cancer cells.
• Solid Tumors: Localized masses of abnormal tissue that can be benign or malignant, forming in various organs, unlike diffuse cancers such as leukemia.
• GPNMB (Glycoprotein Nonmetastatic Melanoma Protein B): A protein found on the surface of certain tumor cells, acting as a specific target for the engineered CAR T-cells.
• Immune Checkpoint Blockers: Therapeutic agents that block inhibitory pathways in the immune system, thereby unleashing T-cells to attack cancer cells more effectively.